Non-psoriatic dermatologic uses of monoclonal antibody therapy Monoclonal antibody therapy

Journal of Dermatological Treatment

Volumn 20, Issue 6, 2009, Pages 319-327

  Sockolov, Mary E ^a   Alikhan, Ali ^a   Zargari, Omid ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pars Clinic   (Iran)

Author keywords

Adalimumab; Anti IgE therapy; Infliximab; Monoclonal antibodies; Omalizumab; Rituximab

Indexed keywords

ADALIMUMAB; CETIRIZINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PARACETAMOL; PREDNISONE; RITUXIMAB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACNE; ACNE CONGLOBATA; ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; ASTHENIA; ATOPIC DERMATITIS; B CELL LYMPHOMA; BACKACHE; BACTERIAL INFECTION; BULLOUS PEMPHIGOID; CHILDHOOD CUTANEOUS POLYARTERITIS NODOSA; CHOLINERGIC URTICARIA; CHRONIC WOUND; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; CROHN DISEASE; CUTANEOUS B CELL LYMPHOMA; CUTANEOUS MASTOCYTOSIS; DERMATOMYOSITIS; DIZZINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRY SKIN; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA NODOSUM; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GRANULOMA ANNULARE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; INFUSION REACTION HEADACHE; INJECTION SITE REACTION; INTERSTITIAL GRANULOMATOUS DERMATITIS; JUVENILE RHEUMATOID ARTHRITIS; LEPROSY; LEUKOCYTOSIS; LICHEN PLANUS; LUNG EMBOLISM; LYMPHOCYTOSIS; MASTOCYTOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOTOR NEUROPATHY; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NECROBIOSIS LIPOIDICA; NONHODGKIN LYMPHOMA; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PITYRIASIS RUBRA PILARIS; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEPSIS; SHIVERING; SINUSITIS; SKIN INFLAMMATION; SKIN LYMPHOMA; SKIN ULCER; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULCERATIVE CUTANEOUS SARCOIDOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTIGO; VISUAL DISORDER; VITILIGO; VOMITING; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HIDRADENITIS SUPPURATIVA; HUMANS; PSORIASIS; PYODERMA GANGRENOSUM; SKIN DISEASES; TREATMENT OUTCOME;

EID: 72449159679     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630902936778     Document Type: Review

References (44)

1. Bohm M, LugerTA. Lichen planus responding to efalizumab. J Am Acad Dermatol. 2007;56:S92-3.
2. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol. 2006;142:680-682
3. Micromedex Healthcare Series (Drugdex). Drug Summary: 1974-2009. Thompson Healthcare. Montvale, New Jersey.
4. Fernandez-vozmediano JM, Armario-hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41.
5. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa:Transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628
6. BrooklynTN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509
7. Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol. 2005;14:401-403
8. Shirakawa M, Uramoto K, Harada FA Treatment of acne conglobata with infliximab. J Am Acad Dermatol. 2006;55: 344-346
9. Kreuter A, GambichlerT, Altmeyer P. Infliximab therapy for interstitial granulomatous dermatitis. J Eur Acad Dermatol Venereol. 2007;21:251-252
10. Vega Gutierrez, J Rodriguez, Prieto MA, Garcia Ruiz JM. Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol. 2007;21:570-l.
11. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31:823-4.
12. FaberWR, Jensema AJ, Goldschmidt WF Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006;355:739.
13. Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J. 2006;3:171-179
14. Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol. 2006;142:1268-1270
15. Ruiz-genao DP, Lopez-estebaranz JL, Naz-villalba E, Gamo-villegas R, Calzado-villarreal L, Pinedo-moraleda F. Pityriasis rubra pilaris successfully treated with infliximab. Acta DermVenereol. 2007;87:552-553
16. Simon JA, Burgos-vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 2008;216:234-235
17. Heffernan MP, AnadkatMJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306-308
18. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274-1275
19. Ortego-centeno N, Callejas-rubio JL, Sanchez-cano D, Caballero-morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2007;21:408-410
20. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006; 142: 110-112
21. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005;5 3:917.
22. Mankad VS, Burks AW. Omalizumab: Other indications and unanswered questions. Clin Rev Allergy Immunol. 2005;29:17-30.
23. Andres C, Belloni B, Mempel M, Ring J. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep. 2008;8:179-180
24. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168-170
25. Spector SL, Tan RA. Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol. 2008;121:784-785
26. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247-249
27. Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 2007;120:213-215
28. Allen KJ, Wolverton SE.The efficacy and safety of rituximab in refractory pemphigus: A review of case reports. J Drugs Dermatol. 2007;6:883-889
29. Diaz LA. Rituximab and pemphigus - A therapeutic advance. N Engl J Med. 2007;357:605-607
30. El Tal Ak, Posner MR, Spigelman Z, Ahmed AR. Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55:449-459 (Pubitemid 44189599)
31. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-1779 (Pubitemid 44631360)
32. Goh MS, Mccormack C, Dinh HV,Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: A prospective open-label pilot study in five patients. Br J Dermatol. 2007;156:990-996
33. FaurschouA, Gniadecki R.Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47:292-294
34. Fernando SL, O'connor KS. Treatment of severe pemphigus foliaceus with rituximab. Med J Aust. 2008;189:289-290
35. SerraoW, Martins A, Paris FR, Lopes MP. Successful treatment of recalcitrant pemphigus foliaceus with rituximab. J Eur Acad Dermatol Venereol. 2008;22:768-770
36. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum. 2005;52:601-607
37. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol. 2007;156:352-356
38. Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z. A new approach on bullous pemphigoid therapy. Ann Oncol. 2008;19:825-826
39. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194-196
40. Wallet-faber N, Franck N, Batteux F, Mateus C, Gilbert D, Carlotti A, et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007;215:252-255
41. Ferrer E, Moral MA Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura. Drug News Perspect. 2006;19: 482-4.
42. Gitelson E, Al-saleemT, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leuk Lymphoma. 2006;47:1902-1907
43. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, VassilakopoulosTP, Kontopidou FN, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77:300-303
44. Herd M, Zillikens D, Borradori L, Bruckner-tuderman L, Burckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6:366-373